TABLE 3.

Antiviral activity of pibrentasvir against HCV replicons containing NS5A genes from HCV-infected patients

HCV genotype	No. of samples	Pibrentasvir EC50 (pM)g
		Range	Median (IQR)
1a	11	0.55–1.7	0.89 (0.54)
1b	8	1.4–3.5	2.7 (1.2)
2aa	6	0.52–1.9	0.93 (0.32)
2bb	11	1.1–1.9	1.3 (0.27)
3ac	14	0.47–1.7	0.71 (0.4)
4ad	8	0.27–1.3	0.50 (0.13)
5a	1	NAh	1.1
6ae	3	0.63–1.0	0.74 (0.2)
6ef	1	NA	0.83
6p	1	NA	0.50

^aFive of the genotype 2a samples had M31 in NS5A. One sample contained NS5A from 2a-JFH-1 and had L31.

^bSeven of the genotype 2b samples had L31, two had M31, and two had M/L31.

^cThree of the genotype 3a samples had A30K, one had A30T, and two had Y93H.

^dOne of the genotype 4a samples had K24R, one had L28M, one had L30R, and one had P58T.

^eTwo of genotype 6a samples had F28L.

^fThe genotype 6e sample had K24R and V28M.

^gAs determined in transient-transfection assays. IQR, interquartile range.

^hNA, not applicable.